Orexigen®
Therapeutics, Inc. OREX and Takeda Pharmaceuticals U.S.A., Inc.
(Takeda), today announced multiple Contrave® (naltrexone sustained release
(SR)/bupropion SR) abstracts accepted for poster presentations and an oral
presentation at the upcoming ObesityWeek meeting. This meeting will be held
November 11-16, 2013 in Atlanta at the Georgia World Congress Center.
Details on the presentation times are as follows:
Oral Presentation: Thursday, November 14, 2013 - Abstract T-36-OR,
Presentation time 3:00-4:30 EST, Georgia World Congress Center
Presenter: Kevin D. Hall, Ph.D.; National Institutes of Health, NIDDK,
Bethesda, MD, USA.
Title: Dynamical Systems Modeling of Caloric Intake and Body Composition with
Combination Naltrexone/Bupropion Therapy
Poster Presentation: Friday, November 15, 2013 - Abstract T-740-P,
Presentation time 12:00-1:30PM EST, Georgia World Congress Center, Exhibit
Hall A
Presenter: Raymond A Plodkowski, MD; Scripps Clinic, La Jolla, CA, USA.
Title: Early achievement of significant weight loss with naltrexone/bupropion
is associated with additional weight loss at one year – an integrated analysis
of four Phase 3 trials
Poster Presentation: Friday, November 15, 2013 - Abstract T-741-P,
Presentation time 12:00-1:30PM EST, Georgia World Congress Center, Exhibit
Hall A
Presenter: Susan McElroy, MD; Research Institute, Lindner Center of HOPE,
Mason, OH, USA.
Title: Naltrexone/bupropion is associated with early and longer-term
improvement in binge eating disorder that is related to improvement in
depression
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in